WEBULL
WebtradeDownload

European Penny Stocks To Consider In October 2026

Simply Wall St · 1d ago

As European markets navigate through heightened inflationary pressures and geopolitical tensions, investors are exploring diverse opportunities beyond traditional large-cap stocks. Penny stocks, often representing smaller or newer companies, remain a relevant investment area despite their somewhat outdated label. These stocks can offer surprising value and potential growth at lower price points when backed by strong financial fundamentals and stability.

Here's a peek at a few of the choices from the screener.

OssDsign (OM:OSSD)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: OssDsign AB (publ) is a company that designs, manufactures, and sells implants and material technology for bone regeneration in the United States, with a market cap of SEK373.36 million.

Operations: The company's revenue is derived entirely from its Medical Products segment, amounting to SEK163.80 million.

Market Cap: SEK373.36M

OssDsign AB, with a market cap of SEK373.36 million, is a debt-free company operating in the medical products sector. Despite being unprofitable and having recently dropped from the S&P Global BMI Index, it maintains sufficient cash runway for over three years if its free cash flow continues to grow. The company's revenue for the first half of 2026 was SEK74.66 million, down from SEK91.02 million in 2025, while net losses remained stable at around SEK22 million. OssDsign's management team has an average tenure of 2.7 years and offers good relative value compared to industry peers despite its challenges.

OM:OSSD Financial Position Analysis as at Oct 2026
OM:OSSD Financial Position Analysis as at Oct 2026

Sprint Bioscience (OM:SPRINT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Sprint Bioscience AB (publ) is a Swedish pharmaceutical company focused on developing drug candidates for cancer treatment, with a market cap of SEK369.30 million.

Operations: Sprint Bioscience AB (publ) has not reported any specific revenue segments.

Market Cap: SEK369.3M

Sprint Bioscience AB, with a market cap of SEK369.30 million, has recently achieved profitability, marking a significant milestone for this pre-revenue biotech firm. Despite its recent earnings success and outstanding Return on Equity of 84%, the company faces challenges with short-term assets of SEK100.6 million not covering long-term liabilities. Its share price remains highly volatile, although volatility has decreased over the past year. Recent financial results show a decline in revenue to SEK0.059 million for the first half of 2026, accompanied by an increased net loss of SEK29.1 million compared to the previous year’s figures.

OM:SPRINT Revenue & Expenses Breakdown as at Oct 2026
OM:SPRINT Revenue & Expenses Breakdown as at Oct 2026

PCC Exol (WSE:PCX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: PCC Exol S.A. manufactures and distributes surfactants both in Poland and internationally, with a market cap of PLN369.17 million.

Operations: The company's revenue segment is Specialty Chemicals, generating PLN1.14 billion.

Market Cap: PLN369.17M

PCC Exol S.A., with a market cap of PLN369.17 million, demonstrates solid financial health, supported by high-quality earnings and a seasoned board with an average tenure of 11.6 years. Recent earnings growth of 16% outpaced its five-year average decline, indicating potential improvement in profitability trends. The company's debt is well-covered by operating cash flow at 27.2%, though the net debt to equity ratio remains high at 51.8%. Despite this leverage, short-term assets exceed both short and long-term liabilities, reflecting robust liquidity. Recent quarterly results show increased sales to PLN335 million and net income doubling year-over-year to PLN20.76 million.

WSE:PCX Debt to Equity History and Analysis as at Oct 2026
WSE:PCX Debt to Equity History and Analysis as at Oct 2026

Make It Happen

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.